Gabriel Leung
President, Pharmaceutical Business

Gabriel Leung is currently President, Pharmaceutical Business at OSI Pharmaceuticals, a leading biotechnology company based in Melville, NY, with therapeutic focus in oncology and diabetes/obesity.

Mr. Leung began his career in the pharmaceutical industry at Sterling Drug Inc., a former division of Eastman Kodak Company, where he gained worldwide business development experience. He then had a distinguished career at Bristol-Myers Squibb where he launched and led the growth of multiple pharmaceutical products in oncology and a variety of primary care and specialty therapeutic areas. Prior to joining OSI, Mr. Leung was Group VP, Global Prescription Business at Pharmacia and was a member of the CEO’s Operating Committee. He headed up Pharmacia’s Oncology Franchise with business and medical affairs operations in over 80 countries. During his tenure at Pharmacia, which ended with the acquisition by Pfizer, he doubled the size of the oncology business to $1.3 billion in revenues, building it into one of the then largest oncology therapeutic companies in the world. From 2007 to 2009, Mr. Leung served on the board of directors of NanoMed, Inc., a start-up biotechnology company based in Kalamazoo, Michigan.

Mr. Leung is a pharmacist, trained at the University of Texas at Austin where he earned his pharmacy degree with High Honors. Following some years of practice in the hospital environment, Mr. Leung earned his M.S. degree at the University of Wisconsin-Madison with concentration in pharmaceutical marketing.

As a current member of the National Cancer Institute Clinical Trial Advisory Committee (NCI CTAC), Mr. Leung serves as an advisor to the NCI Director. He is an active member and a member of the Nominating Committee of C-Change (www.cchangetogether.org), a national initiative chaired by former President George Bush and Mrs. Barbara Bush with the goal of eliminating cancer as a major public health problem. Also, following his 2-year term as the founding chairman, he is now vice-chair of the Life Sciences Consortium, an initiative of the CEO Roundtable on Cancer (www.ceoroundtableoncancer.org). In this role, he helps lead an industry-wide effort to facilitate cross-company and cross-sector collaboration and to help expedite oncology drug discovery and development. Mr. Leung is a distinguished speaker on healthcare/industry issues and has lectured at major universities.